Patents by Inventor Magdalena Kovacsovics

Magdalena Kovacsovics has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11197889
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: December 14, 2021
    Assignees: ABT Holding Company, Oregon Health & Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Publication number: 20210346429
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 11, 2021
    Applicants: ABT Holding Company, Oregon Health & Science University
    Inventors: Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Robert DEANS, Wouter VAN'T HOF
  • Publication number: 20210228626
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert DEANS, Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Wouter VAN'T HOF
  • Publication number: 20210205359
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: January 12, 2021
    Publication date: July 8, 2021
    Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert Deans, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Wouter Van't Hof
  • Patent number: 11000546
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: May 11, 2021
    Assignees: ATHERSYS, INC., OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert Deans, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Wouter Van't Hof
  • Publication number: 20180318346
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: May 3, 2018
    Publication date: November 8, 2018
    Applicants: ATHERSYS, INC., OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert DEANS, Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Wouter VAN'T HOF
  • Patent number: 9962407
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: May 8, 2018
    Assignees: Athersys, Inc., Oregon Health and Science University
    Inventors: Robert Deans, Wouter Van't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
  • Publication number: 20180055881
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Applicants: ATHERSYS, INC., OREGON HEALTH AND SCIENCE UNIVERSITY
    Inventors: Richard MAZIARZ, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Patent number: 9828432
    Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: November 28, 2017
    Assignee: PROVIDENCE HEALTH & SERVICES—OREGON
    Inventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg
  • Patent number: 9808485
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: November 7, 2017
    Assignees: Athersys, Inc., Oregon Health And Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Publication number: 20150118193
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: July 30, 2013
    Publication date: April 30, 2015
    Applicant: Oregon Health And Science University
    Inventors: Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Robert DEANS, Wouter VAN'T HOF
  • Publication number: 20150098942
    Abstract: OX40 is a potent immune stimulating target. Provided herein are methods for the treatment of cancer patients using (3X40 agonists methods to predict clinical outcome of the treatment by correlation of the treatment and an increase in OX40-induced T cell proliferation.
    Type: Application
    Filed: February 6, 2012
    Publication date: April 9, 2015
    Applicant: Providence Health & Services - Oregon d/b/a Providence Portland Medical Center
    Inventors: Brendan Curti, Magdalena Kovacsovics-Bankowski, Ed Walker, Josh Walker, Andy Weinberg
  • Publication number: 20120135043
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 31, 2012
    Inventors: Richard MAZIARZ, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Patent number: 8147824
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: April 3, 2012
    Assignees: Athersys, Inc., Oregon Health and Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Publication number: 20090104163
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: November 9, 2006
    Publication date: April 23, 2009
    Applicants: ATHERSYS, INC., OREGON HEALTH AND SCIENCE UNIVERSITY
    Inventors: Robert Deans, Wouter Vant't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
  • Publication number: 20060263337
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: November 9, 2005
    Publication date: November 23, 2006
    Inventors: Richard Maziarz, Philip Streeter, Magdalena Kovacsovics, Robert Deans, Wouter Van't Hof